1
No serious adverse reactions were noted in patients receiving HD- or SD-CAP therapy.
2
Caregiving for disabled older adults receiving HD may be associated with significant challenges for caregivers.
3
In this cohort of patients receiving HD-CTX as first-line treatment, 63% achieved long-term progression-free survival.
4
Thirty-four patients who received HD-CAP were compared with 63 patients who received standard dose (SD)-CAP.
5
Due to imbalances between patients, a propensity score for receiving HD carbapenem was added to the model.
6
Conclusion: Presepsin levels were markedly high in patients receiving HD, similar to values seen in patients with severe sepsis or septic shock.
7
The number of U.S. homes receiving HD signals is expected to reach as high as 40 million by 2012, researchers forecast.